Nicholas Montgomery
Family · Bedford, PANPI 1003419466
Payments from drug & device makers
Across 195 payments — averaging $15.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$866
- Novo Nordisk$455
- Amgen$218
- Indivior Inc.$208
- Pfizer$174
- Gilead$157
- plus $1K from 20 others
What the payments were for
- Food & beverage$3,03798%
- Education$682%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 61 | $866 |
| Novo Nordisk | 27 | $455 |
| Amgen | 12 | $218 |
| Indivior Inc. | 11 | $208 |
| Pfizer | 14 | $174 |
| Gilead | 8 | $157 |
| Exact Sciences | 7 | $132 |
| Lilly USA, LLC | 8 | $126 |
| Xeris Pharmaceuticals, Inc. | 7 | $120 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 6 | $103 |
| Merck | 5 | $85 |
| Novartis | 6 | $85 |
| Astellas Pharma US Inc | 4 | $77 |
| Dexcom, Inc. | 3 | $53 |
| Advanced Respiratory, Inc | 2 | $50 |
| GSK | 2 | $33 |
| Sanofi Pasteur Inc. | 2 | $26 |
| Medtronic | 2 | $25 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $19 |
| Boston Scientific | 1 | $16 |
| Corcept Therapeutics | 1 | $16 |
| Cequr Corporation | 1 | $14 |
| Philips North America LLC | 1 | $13 |
| Corium, LLC | 1 | $12 |
| AstraZeneca | 1 | $12 |
| Johnson & Johnson | 1 | $11 |
How this compares
$3,105 in reported general payments places this provider in the 85th percentile of 4,717 family providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 165 | $132,766 |
| EliquisApixaban | 103 | $75,693 |
| OzempicSemaglutide | 67 | $64,986 |
| TrulicityDulaglutide | 44 | $42,802 |
| RybelsusSemaglutide | 19 | $26,238 |
| MounjaroTirzepatide | 19 | $26,058 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 23 | $19,228 |
| XareltoRivaroxaban | 18 | $15,327 |
| EntrestoSacubitril/Valsartan | 21 | $14,768 |
| Breo ElliptaFluticasone/Vilanterol | 38 | $14,640 |
| TradjentaLinagliptin | 16 | $10,050 |
| BelbucaBuprenorphine Hcl | 11 | $9,321 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 16 | $9,130 |
| Humalog Kwikpen U-100Insulin Lispro | 38 | $8,094 |
| Aimovig AutoinjectorErenumab-Aooe | 11 | $8,071 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $455 | $91,22386 claims |
| PfizerEliquis | $174 | $75,693103 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $126 | $68,86063 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $33 | $33,86761 claims |
| Johnson & JohnsonXarelto | $11 | $15,32718 claims |
| NovartisEntresto | $85 | $14,76821 claims |
| AstraZenecaFarxiga, Symbicort | $12 | $11,81332 claims |
| MerckJanumet Xr, Belsomra | $85 | $9,37725 claims |
| AbbVieSavella, Synthroid | $866 | $8,03546 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 4,717 family providers in Pennsylvania.
Other family in Bedford
- Kathleen ScholzPittsburgh$397K
- Shannon FitzgeraldAllison Park$370K
- Stephanie HarshbargerCamp Hill$317K
- Whitney BowlesFort Washington$253K
- Kweilynn GreenePittsburgh$139K
- Jessica LindenbergerPittsburgh$131K
- Kami NestlerWilkes Barre$129K
- Bethany ThomasPhiladelphia$126K
- Margaret RosenzweigPittsburgh$89K
- Amanda GrippoDickson Cty$86K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.